New Options in Constipation Management
| Autor: | Pamela Gamier, Mellar P. Davis |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Constipation Naloxegol chemistry.chemical_compound Elobixibat Gastrointestinal Agents Neoplasms medicine Alvimopan Humans Chloride Channel Agonists Intensive care medicine Linaclotide Randomized Controlled Trials as Topic Membrane Glycoproteins Prucalopride business.industry Probiotics Methylnaltrexone Lubiprostone Analgesics Opioid Oncology chemistry Laxatives Anesthesia medicine.symptom Carrier Proteins business medicine.drug |
| Zdroj: | Current Oncology Reports. 17 |
| ISSN: | 1534-6269 1523-3790 |
| DOI: | 10.1007/s11912-015-0481-x |
| Popis: | Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink